GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). It occurs naturally in human plasma, where it was first identified in 1973; its levels decline with age.1
The peptide binds a copper ion, forming a characteristic blue complex, and copper is a cofactor for many enzymes involved in skin and connective-tissue repair.1
GHK-Cu is widely used as a cosmetic topical ingredient, but it is not an FDA-approved drug for any medical indication.23
In plain English: GHK-Cu is a tiny peptide joined to copper. Your body makes it, and it's popular in skin creams.
What the research shows - and what it doesn't
Laboratory and animal studies associate GHK-Cu with collagen synthesis, wound repair, and broad effects on gene expression.12
There is also some human cosmetic research on topical creams, and at least one clinical trial is registered for a topical GHK-Cu wound-healing gel.3
The regulatory question here specifically concerns the injectable form (topical cosmetic use is regulated differently). For injectable GHK-Cu there are not large, well-controlled human trials establishing safety and effectiveness as a compounded drug.23
Why GHK-Cu already has a cult following
GHK-Cu is the rare peptide with a foot in the real world: as a copper-bound tripeptide it's a darling of high-end skincare, credited in research with boosting collagen, smoothing skin, and speeding wound repair - and it naturally declines as we age.12
That "restore what youth had" story is powerful, and the skin research is substantial. The compounding question is narrower:
the
injectable form, where the rigorous human data thins out.3
How to read peptide research. Animal-study and cell-study findings describe what happened in a controlled experiment. They are a starting point for investigation, not evidence that a compound works - or is safe - in humans. Peppies does not claim any peptide treats, cures, or prevents any condition.
In plain English: Research links it to firmer skin, more collagen, and faster wound healing. The question here is the shot (injectable) form, which has less human proof.
Is GHK-Cu legal in 2026?
Here is the direct answer as of July 2026:
It is not an FDA-approved drug. There is no approved GHK-Cu product for any medical use.
Cosmetic use is regulated separately. Topical GHK-Cu is sold as a cosmetic ingredient; that status does not make an injectable drug form FDA-approved. The FDA's Category 2 listing applied to the injectable form.4
It has no cleared compounding pathway. GHK-Cu was in "Category 2" of the FDA's interim 503A bulk-substances list (substances raising significant safety concerns). The FDA removed it - with eleven other peptides - from Category 2 in April 2026, but removal did not place it on the approved list.56
It is not (yet) on the July 2026 agenda. Only seven of the twelve were scheduled for the July 23-24, 2026 advisory meeting; GHK-Cu is among the five expected to be taken up in a later review.54
In plain terms, GHK-Cu sits in a regulatory gap - out of the explicitly-restricted bucket, but not in any approved one, and still awaiting its own review.
This section is educational and is not legal advice. Rules can vary and change; consult a qualified professional for your situation.
In plain English: Skin creams with it are sold as cosmetics. The injectable drug form is not approved and has no legal made-to-order path yet.
The regulatory timeline
Sep 2023
FDA places this and other peptides in Category 2 of the interim 503A bulks list, citing safety concerns.5
Apr 2026
FDA removes 12 peptides - including this one - from Category 2. Seven are referred to a July 2026 advisory meeting; the remaining five, including this one, are set aside for a later review.56
Later review (reported as early 2027)
The Pharmacy Compounding Advisory Committee is expected to take up the remaining peptides - including this one - at a subsequent meeting. As of July 2026, FDA had not yet posted an official meeting notice or evaluated-use chart for that session.45
After that meeting
Any committee vote is advisory only. The FDA then decides whether to begin formal rulemaking to add (or not add) the peptide to the 503A list - the stage where public comment carries legal weight.7
The "early 2027" timing is reported by legal and industry analysts of the April 2026 action; treat it as anticipated rather than an officially scheduled FDA date until a Federal Register notice confirms it.45
Where the public comes in
Because this peptide is not on the July 2026 agenda, its public docket has not opened yet. When the FDA schedules its review - and, more importantly, if it later opens formal rulemaking - there will be a public comment window. That rulemaking window is the one that carries legal weight, and it is the moment Peppies is tracking.
Want to know the moment you can comment?
Join the list and we'll send a clear, step-by-step heads-up when a comment window opens - for this peptide and the rest. See also our how-to-comment guide.
Topical GHK-Cu is sold as a cosmetic ingredient. The injectable form is not an FDA-approved drug and has no cleared compounding pathway; it was removed from Category 2 (injectable) in April 2026 but is not on the July 2026 agenda.54
Isn't GHK-Cu already in skincare?
Yes - as a topical cosmetic ingredient, which is regulated differently from injectable drugs. The compounding review concerns the injectable form.4
When will the FDA review injectable GHK-Cu?
Not on the July 2026 agenda. A later review is anticipated (reported as early 2027); no official FDA date was confirmed as of July 2026.45
Where to learn more
Want to dig into the primary science yourself? These are neutral, authoritative starting points - no sales pitch, just the record:
We link only to independent, authoritative sources - U.S. and international (NIH, FDA, Europe PMC/EMBL-EBI, and the EU/U.S. trial registries) - never to sellers.
Frier Levitt. "FDA to Remove 12 Peptides from the Category 2 'Do Not Compound' List: What It Means for Pharmacies," 2026. frierlevitt.comwww.frierlevitt.com
Hyman, Phelps & McNamara. "FDA's Pep(tide) Rally: What Compounders and Industry Need to Know." FDA Law Blog, April 2026 - 12 peptides removed from Category 2; a subset referred to the July 2026 PCAC and the remainder to a later review. thefdalawblog.comwww.thefdalawblog.com
Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting ... Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." April 16, 2026. federalregister.govwww.federalregister.gov
U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A" (interim list and categories). fda.gov - 503A bulk drug substanceswww.fda.gov
